Navigation Links
New drug combination therapy developed to treat leukemia
Date:4/17/2013

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent.

In the study, published in the journal Cancer Research, researchers combined the drug ABT-737 with another agent BEZ235. ABT-737 targets proteins known as B-cell lymphoma 2 (Bcl-2) and Bcl-xL, which prevent apoptosis, a form of cell suicide, in cancer cells. BEZ235 directly inhibits the PI3K/AKT/mTOR pathway, and as a result, reduces the expression of another anti-apoptotic protein known as Mcl-1, which is not targeted by ABT-737. Among their many functions, signaling pathways regulate biological processes required for cellular survival. The PI3K/AKT/mTOR pathway helps keep apoptosis in check, in part, by controlling the production of Mcl-1. However, the pathway can become dysregulated in cancer, and in so doing, contribute to uncontrolled tumor growth and resistance to conventional cancer therapies. It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations. Significantly, disabling both anti-apoptotic proteins, Bcl-2 and Bcl-xL, in conjunction with Mcl-1, caused profound cell death of leukemia cells in the test tube as well as in animal models of AML.

"This study builds on many years of work in our laboratory investigating the mechanisms that regulate apoptosis in human leukemia cells. To the best of our knowledge, it is the first to raise the possibility that activation of the P13K/AKT/mTOR pathway, rather than genetic mutations within the pathway, may represent the best predictor of leukemia cell responses to these targeted agents," says one of the study's key researchers Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, program co-leader of Developmental Therapeutics and Cancer Cell Signaling research member at VCU Massey Cancer Center. "These findings could lead to a new therapeutic strategy for patients with AML and potentially other diseases by targeting patients whose leukemia cells display activation of a specific survival pathway."

Grant's team made another discovery that helped explain the new therapy's effectiveness. They found that the therapy releases and/or activates the pro-apoptotic proteins Bim, Bak and Bax, which help trigger apoptosis. Thus, in addition to disabling major pro-survival proteins, the combination therapy also helps to unleash several additional proteins that promote apoptosis.

Moving forward, Grant and his team hope to work with pharmaceutical companies and the National Cancer Institute to develop strategies combining inhibitors of the PI3K/AKT/mTOR pathway with Bcl-2 family antagonists for the treatment of patients with AML.


'/>"/>

Contact: Alaina Farrish
akfarrish@vcu.edu
804-628-4578
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Immunotherapy for elderly cancer patients finds new promise in drug combination
2. Combination of 2 drugs reverses liver tumors
3. Cancer vaccine combination therapy shows survival benefit in breast cancer
4. Discovery suggests new combination therapy strategy for basal-like breast cancers
5. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
8. Combination peptide therapies might offer more effective, less toxic cancer treatment
9. Drug combination against NRAS-mutant melanoma discovered
10. Combination treatment may improve survival of breast cancer patients with brain metastases
11. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive ... Dr. Brian Seese leads the practice as a skilled and highly credentialed dentist who ... by Seese serves patients of all ages with excellence in general, restorative, and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... should be asking before selecting an FDA approval pathway? , How should ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... 2017 season , Trinity Health and the U.S. Soccer Foundation announced today that ... in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/16/2017)... (PRWEB) , ... February 17, 2017 , ... ... their experience can last long after their final treatments. Physician researchers at ... neuro-emotional technique (NET), a mind-body therapy, for efficacy in reducing symptoms of traumatic ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  Express Scripts (NASDAQ: ESRX ) was recognized ... Companies within the Health Care: Pharmacy and Other Services category. ... World,s Most Admired Companies," said Tim Wentworth , CEO and ... passion of our 26,000 employees to make medicine more affordable and ... ...
(Date:2/16/2017)...  Prescription pain medications provided by "physicians in the ... long-term opioid use to take hold," according to a ... of The New England Journal of Medicine ... in acute pain than in almost any other medical ... of the American College of Emergency Physicians. "The challenge ...
(Date:2/16/2017)... , Feb. 16, 2017   Spectralink ... solutions for the healthcare, retail, manufacturing and hospitality ... on the performance and symbology support features of ... a dual-mode camera/barcode scanner. The study, conducted by ... the PIVOT:SC to two phones with dedicated hardware ...
Breaking Medicine Technology: